Amgen has moved closer to a second indication for its B cell-depleting therapy Uplizna, acquired as part of its $27.8 billion takeover of Horizon Therapeutics last year, after positive results in ...

Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...

Amgen shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and rocatinlimab, ...

The uplizna market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...